CTI BioPharma Corp.
CTIC · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $24 | $30 | $32 | $66 |
| Short-Term Investments | $35 | $50 | $50 | $30 |
| Receivables | $23 | $15 | $11 | $8 |
| Inventory | $1 | $1 | $1 | $1 |
| Other Curr. Assets | $4 | $3 | $4 | $3 |
| Total Curr. Assets | $86 | $99 | $97 | $107 |
| Property Plant & Equip (Net) | $2 | $2 | $2 | $2 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $23 | $23 | $24 | $24 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $1 |
| Total NC Assets | $26 | $27 | $27 | $27 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $112 | $126 | $123 | $135 |
| Liabilities | – | – | – | – |
| Payables | $2 | $2 | $2 | $3 |
| Short-Term Debt | $48 | $48 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $18 | $31 | $27 | $27 |
| Total Curr. Liab. | $68 | $81 | $30 | $30 |
| LT Debt | $0 | $0 | $48 | $49 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $69 | $62 | $63 | $61 |
| Total NC Liab. | $69 | $62 | $111 | $110 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $138 | $144 | $140 | $140 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$2,532 | -$2,519 | -$2,501 | -$2,486 |
| AOCI | -$0 | -$0 | -$0 | -$0 |
| Other Equity | $2,507 | $2,501 | $2,485 | $2,480 |
| Total Equity | -$25 | -$18 | -$17 | -$5 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $112 | $126 | $123 | $135 |
| Net Debt | $24 | $18 | $16 | -$17 |